


Supposed treatment with anticoagulants



| Relevant anticoagulant drug-levels | |
|------------------------------------|--|
| UFH: | aPTT > internal reference (e.g. 35 s) anti-Xa activity > 0.1 U/mL (thrombin time > internal reference, e.g. 30s) |
| LMWH: | anti-Xa activity > 0.15 U/mL |
| VKA: | INR > 1.3 (PT > internal reference; Quick-test < 70%) |
| Rivaroxaban: | anti-Xa activity > 30-50 ng/mL |
| Apixaban: | anti-Xa activity > 30-50 ng/mL |
| Dabigatran: | diluted thrombin time (or ecarin clotting time) > 30-50 ng/mL |
| Edoxaban: | anti-Xa activity > 30-50 ng/mL |

* time interval until laboratory results are available

| Reversal agents | |
|--|--|
| UFH: | <ul style="list-style-type: none"> • 1:1 units of protamin IV per unit UFH given in previous 3 hours (if stop within previous hour or anti-Xa activity > 0.35 U/mL), 5000 IU maximum • ½:1 units of protamin IV per unit UFH given in previous 3 hours (if UFH stop within previous 3 hours or anti-Xa activity > 0.1 U/mL), 2500 IU maximum |
| LMWH: | <ul style="list-style-type: none"> • 5000 IU protamine sulphate IV if therapeutic dose LMWH and last application < 8h or anti-Xa > 0.5 U/mL • 2500 IU protamine sulphate IV if therapeutic dose LMWH and last application < 12h or anti-Xa > 0.3 U/mL |
| VKA: | <ul style="list-style-type: none"> • Prothrombin complex concentrate: 2400 IU IV (or 30 U/kg body weight in patients below 30 kg) • Vitamin K 10 mg IV (daily until recovery) |
| Rivaroxaban/ Apixaban/ Edoxaban: | <ul style="list-style-type: none"> • Prothrombin complex concentrate: 50 IU per kg body weight IV |
| Dabigatran: | <ul style="list-style-type: none"> • Idarucizumab (Praxbind®) 2 x 2.5 g IV |